Samsung Bioepis has just reached a thrilling milestone by securing Japan's regulatory approval for its Stelara biosimilar, opening the door to a powerful presence in Asia's rapidly growing biologics market, The Korea Herald reports
Samsung Bioepis has just reached a thrilling milestone by securing Japan's regulatory approval for its Stelara biosimilar, opening the door to a powerful presence in Asia's rapidly growing biologics market, The Korea Herald reports
